BioSpace News Archive

Bristol-Myers Squibb Company (NYSE: BMY) will take part in Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11, 2019, in Rancho Palos Verdes, CA.

Colorado BioScience Association (CBSA) today launched the new issue of its annual magazine, BioScience Colorado: Collaborative by Nature, at this week’s 2019 BIO International Convention in Philadelphia.

Reaction Biology Corporation (“RBC”), a leading contract research organization providing early stage drug discovery services, announced that it has received a subcontract from Leidos Biomedical Research, Inc., which operates the Frederick National Laboratory for Cancer Research for the National Cancer Institute

Morgan Stanley today announced the launch of Morgan Stanley GIFT Cures℠ powered by Harrington Discovery Institute, the first special interest program of The Morgan Stanley Global Impact Funding Trust (Morgan Stanley GIFT) that is dedicated to advancing the development of research discoveries into new cures and treatments for a broad range of diseases.

The Biotechnology Innovation Organization released “Transforming Ideas into Advances: Best Practices in State and Regional Bioscience Economic Development Initiatives” at the 2019 BIO International Convention.

Harriet Schleifer has been elected president of the American Jewish Committee, the leading global Jewish advocacy organization.

Neurocrine Biosciences, Inc. will present at the Goldman Sachs 40th Annual Global Healthcare Conference at 10:00 a.m. PT (1:00 p.m. ET) on Tuesday, June 11, 2019, in Rancho Palos Verdes, Calif. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, of Neurocrine Biosciences will present at the conference.

CollPlant, a regenerative medicine company, announced that the results from a clinical study conducted with its VergenixFG advanced wound care product will be presented at the 29th Conference of the European Wound Management Association.

Titan Pharmaceuticals, Inc. announced that it has executed a pharmacy services agreement with Southside Specialty Pharmacy, further expanding access to treatment with Probuphine implant, Titan’s novel maintenance treatment for Opioid Use Disorder in eligible patients.

Results from cohort with median follow up of 3.2 years presented at 2019 ASCO Annual Meeting